NASDAQ:SEPN

Septerna Q1 2026 Earnings Results & Report

Septerna logo
$41.67 -0.93 (-2.18%)
Closing price 04:00 PM Eastern
Extended Trading
$41.64 -0.02 (-0.06%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Septerna beat analyst expectations on both earnings and revenue in its Q1 2026 results, released May 11, 2026. The company reported EPS of -$0.19 versus the -$0.4167 consensus estimate, while revenue of $26.52 million topped the $16.98 million estimate by $9.55 million.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Septerna EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.4167
Beat/Miss
Beat by +$0.2267
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Septerna Revenue Results

Actual Revenue
$26.52 million
Expected Revenue
$16.98 million
Beat/Miss
Beat by +$9.55 million
YoY Revenue Growth
N/A

Septerna Q1 2026 Earnings FAQ

Septerna (NASDAQ:SEPN) reported earnings of -$0.19 per share for Q1 2026, beating the consensus estimate of -$0.4167. The report was announced on Monday, May 11, 2026.

Septerna reported revenue of $26.52 million for Q1 2026, against a consensus estimate of $16.98 million.

Septerna Earnings Headlines

My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
Septerna (NASDAQ:SEPN) Director Sells $3,934,723.80 in Stock
Septerna FY2026 Earnings Forecast Lowered by HC Wainwright
Septerna (NASDAQ:SEPN) Downgraded by Wall Street Zen to Sell
See More Septerna Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Septerna? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Septerna and other key companies, straight to your email.

About Septerna

Septerna (NASDAQ:SEPN) is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California.

Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.

Founded in 2021, Septerna has no marketed products; its work is focused on research and clinical development. The company has also pursued collaborations to apply its GPCR discovery capabilities to additional therapeutic programs.

View Septerna Profile